News

The 3-part educational program is sponsored by Genentech.

Individuals whose mothers had pregestational diabetes mellitus had a statistically significant 2.3-fold increased risk of developing multiple sclerosis.

Women with HDP were found to perform worse on cognitive tests 15 years after delivery than their counterparts.

The chief medical officer of CND Life Sciences and medical director of Honor Health Neurology spoke to the role synuclein has played in advancing PD diagnosis.

Neurological disability, as assessed by EDSS, was also found to be associated with higher levels of MS fatigue.

The executive director of the Norman Fixel Institute for Neurological Diseases explained how disease-based registries play a crucial part in changing the approval system for neurologic devices in rare diseases.

Raymond Sanchez, MD, chief medical officer of Cerevel Therapeutics, discussed tavapadon, a drug intended to treat Parkinson disease that is currently being tested in a slew of clinical trials.

Neuronaute consists of a smart shirt and smart cap containing biosensors that monitor physiological characteristics, such as muscle activity and heart and respiratory rate.

Objective reduction in tremor was accompanied by improvement in specific motor tasks and a larger proportion of patients in the botulinum neurotoxin group reporting a global subjective improvement in symptoms.

In addition to the device showing a safe profile, it helped patients with pain relief from their migraine and increased functional ability.

An analysis of MSBase data including more than 14,000 patients with MS suggests that disease-modifying therapies are effective in improving disability outcomes in relapsing disease.

Researchers from Northwestern University found nilotinib had an acceptable safety profile, but lacked efficacy that would encourage further study in patients with Parkinson disease.

The assistant professor of neurology and anesthesiology at Harvard Medical School provided context on the potential of motor neuron excitability in patients with ALS.

The agent will aim to be the first and only FDA-approved liquid formulation of topiramate, with a PDUFA date set in Q3 of 2021.

The director of the Healey & AMG Center for ALS spoke to the recent topline results of a phase 3 study of NurOwn in patients with the neuromuscular disease.

Here's what is coming soon to NeurologyLive.

The director of the Mid-Atlantic Epilepsy and Sleep Center urged physicians to try and find the right medications for their patients as early as possible.

Both ongoing ACT-AD and LIFT-AD studies are assessing Athira’s investigational therapy ATH-1017.

Researchers from the University of Turin also found that an NEFH variant showed a protective association with ALS.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 1, 2021.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how his team succeeded at titrating cenobamate early in the study.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Leigh Charvet, PhD.

Catch up on the best and most listened to episodes of the NeurologyLive Mind Moments podcast, featuring exclusive interviews with experts in neurology.

Increasing the use and accessibility of mechanical thrombectomy may reduce the burden of stroke on a global scale.